highperformr logo

Cambrian Asset Management's Overview

Total employees9
HeadquartersNew York
Founded2017

Cambrian BioPharma is a clinical-stage biopharmaceutical company dedicated to developing therapeutics that treat and prevent diseases of aging. Their mission is to extend healthspan – the period of life spent in good health – by advancing a diverse portfolio of novel drug candidates. Cambrian operates on a 'Distributed Drug Development' (DEAL - Discovery, Evaluation, Acceleration, and Launch) model, identifying and nurturing promising scientific breakthroughs from various sources to build its pipeline companies.

Where is Cambrian Asset Management's Headquarters?

HQ Function

The New York headquarters serves as the central hub for Cambrian BioPharma's global operations, overseeing strategic direction, R&D pipeline management, corporate development, investor relations, and the coordination of its distributed drug discovery model.

Notable Features:

Located in a modern office building in the Hudson Square neighborhood, the headquarters provides a contemporary workspace designed to foster collaboration and innovation. Its location offers access to a rich ecosystem of scientific talent, financial institutions, and research organizations.

Work Culture:

Cambrian BioPharma fosters a highly ambitious, science-first work culture. Employees are driven by the mission to extend healthspan, working in a dynamic, fast-paced environment that encourages innovation, rigorous research, and cross-functional collaboration. Given its distributed model, effective communication and project management are key cultural aspects.

HQ Significance:

The headquarters is the nerve center for Cambrian's unique approach to drug development, managing a portfolio of pipeline companies and collaborations aimed at tackling the multifaceted aspects of aging. Its New York presence is vital for attracting top talent and securing investment.

Values Reflected in HQ: The headquarters' setup and location likely reflect Cambrian's core values of innovation, scientific excellence, collaboration, agility, and a commitment to addressing significant unmet medical needs in aging.

Location:

Cambrian BioPharma primarily operates through its New York headquarters and a distributed R&D model. This involves identifying, funding, and developing scientific assets from research institutions and biotech partners globally. While its corporate hub is in the US, its scientific sourcing, collaborations, and the ultimate impact of its therapies are aimed at a global scale to address age-related diseases worldwide.

Street Address:

180 Varick Street, Suite 1228

City:

New York

State/Province:

NY

Country:

USA

Cambrian Asset Management's Global Presence

Buying Intent Signals for Cambrian Asset Management

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cambrian Asset Management

As of April 2025, Cambrian Asset Management' leadership includes:

Brent Saunders - Executive Chairman
James Peyer, PhD - Chief Executive Officer
Georg C. Terstappen, PhD - Chief Scientific Officer
Juliette Han, PhD, JD, CLP - Chief Business Officer
Annelise Lilhendahl, MBA - Chief Operating Officer

Investors of Cambrian Asset Management

Cambrian Asset Management has been backed by several prominent investors over the years, including:

Apeiron Investment Group
Future Ventures
Catalio Capital Management
SALT Fund
Kizoo Technology Capital
Brent Saunders
Christian Angermayer
Richard Klausner
Peter Attia

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits0

The most notable executive update in the past year was the appointment of Brent Saunders as Executive Chairman in January 2024, a significant addition bringing extensive biopharma leadership experience to Cambrian BioPharma. No major executive departures were publicly announced during this period.

New Appointments:

Brent Saunders, Brent Saunders joined Cambrian BioPharma as Executive Chairman, bringing decades of experience in the pharmaceutical industry to help steer the company's mission in longevity science.

Technology (Tech Stack) used by Cambrian Asset Management

Discover the tools Cambrian Asset Management uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cambrian Asset Management Email Formats and Examples

Based on publicly available information and common industry practices, Cambrian BioPharma likely utilizes a straightforward email format. The most probable format is using the first name of the employee.

[first]@cambrianbio.com

Format

james@cambrianbio.com

Example

85%

Success rate

News and media

PR NewswireJanuary 9, 2024

Cambrian BioPharma news title: Brent Saunders Joins Cambrian BioPharma as Executive Chairman

Cambrian BioPharma announced that Brent Saunders has joined the company as Executive Chairman. Saunders, a renowned leader in the biopharmaceutical industry, will bring his extensive experience to guide Cambrian's strategy and growth in developing medicines to target diseases of aging....more

PR NewswireNovember 9, 2023

Cambrian BioPharma news title: Cambrian BioPharma Announces Creation of Telomere Therapeutics with Exclusive License to Novel Telomerase Gene Therapy Technology from University of Pittsburgh

Cambrian BioPharma launched Telomere Therapeutics, Inc., a new pipeline company. Telomere Therapeutics will focus on developing novel gene therapies targeting telomere biology, based on technology exclusively licensed from the University of Pittsburgh, to treat and prevent age-related diseases....more

BioSpaceFebruary 7, 2023

Cambrian BioPharma news title: Cambrian BioPharma Announces Publication Highlighting the Development of Novel, Selective mTORC1 Inhibitors

Cambrian BioPharma announced a publication detailing the development of novel, highly selective mTORC1 inhibitors. These compounds show potential for improved safety profiles in treating age-related diseases by minimizing off-target effects associated with earlier mTOR inhibitors....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cambrian Asset Management, are just a search away.